Interim Results

-Interim Results for the six months ended 31 October 2017

-OVARIAN CANCER CLINICAL STUDIES SUCCESSFULLY COMPLETED

-ACQUISITION ADDS DOWNSTREAM ANALYSIS TO PARSORTIX CTC HARVESTING PROVIDING COMPLETE ‘SAMPLE TO ANSWER’ CAPABILITY

-INSTITUTIONAL REVIEW BOARD APPROVALS RECEIVED FOR FDA STUDY

GUILDFORD, SURREY / ACCESSWIRE / January 31, 2018 / ANGLE plc (AIM: AGL and OTCQX: ANPCY), a world-leading liquid biopsy company, today announces its unaudited interim financial results for the six months ended 31 October 2017.

Operational Highlights

• Clinical evidence from successful US and European ovarian cancer studies in 400 patients, demonstrating potential for a ParsortixTM-based blood test to
significantly out-perform current standard of care in discriminating between benign and malignant pelvic masses

• Acquisition of Axela Inc. downstream analysis platform assets (known as the Ziplex® platform) for £3.6 million, expands the Company’s liquid biopsy
capabilities to enable unique ‘sample to answer’ solution with multiplex gene and protein expression

• Extensive work towards FDA Class II clearance in metastatic breast cancer completed with analytical studies in progress and clinical study commencing
patient enrolment shortly
– Number 1 cancer centre in the United States, MD Anderson leading the clinical study primary endpoint analysis
– Detailed protocols fully developed and agreed
– Institutional Review Board (IRB) approvals received from MD Anderson and the University of Rochester Wilmot Cancer Center

• The Company’s ISO13485 quality management system, which supports regulatory clearance for CE Mark and FDA, successfully completed BSI audit in
January 2018 and has been approved for transition to the new ISO13485:2016 standard ahead of schedule

• Signed collaborations with leading, global healthcare companies
– Co-marketing partnership with QIAGEN, a world-leading molecular testing company
– Collaboration with Philips in breast and rectal cancer, post period end

• Growing body of published evidence, from internationally-recognised cancer centres during and post period end, validating the potential of the Parsortix
system as a leading liquid biopsy platform for, amongst others, ovarian, breast and prostate cancers
– Installed base of over 145 Parsortix instruments deployed worldwide (H1 2017: 120) with over 39,000 blood separations completed (H1 2017: 22,000)
– Extensive research usage is expected to drive increasing revenues as new protocols are developed and adopted

Click on, or paste the following link into your web browser, to view the associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/4022D_1-2018-1-30.pdf

This information is provided by RNS
The company news service from the London Stock Exchange

SOURCE: ANGLE plc

ReleaseID: 487422